Clover Health to Attend the Barclays Global Healthcare Conference on March 10, 2021

NASHVILLE, Tenn., March 03, 2021 (GLOBE NEWSWIRE) — Clover Health (Nasdaq: CLOV), an innovative technology company improving health outcomes for America’s seniors, today announced that company executives will present at the Barclays Global Healthcare Conference on Wednesday, March 10 at 10:55 a.m. Eastern Time.

A live webcast of the presentation will be accessible from Clover Health’s investor website, or can be accessed directly by clicking this link. A replay of the presentation will be available from the same website.

About Clover Health

Clover Health (Nasdaq: CLOV) is a healthcare technology company with a deeply rooted mission of improving every life. Clover uses its proprietary technology platform to collect, structure, and analyze health and behavioral data to improve medical outcomes and lower costs for patients. As a company whose business goals fully align with its members’ health needs, Clover works with members and their doctors to become a valued partner. This trust is built by proactively identifying at-risk individuals and teaming up with physicians to accelerate care coordination and simultaneously improve health outcomes and reduce avoidable costs. Clover has offices in San Francisco, Jersey City, Nashville and Hong Kong.

Contacts:
Investor Relations:
[email protected]

Press Contact:
Andrew Still-Baxter
[email protected]

 



Radius Health, Inc. Announces $175 Million Financing Transaction

  • Repurchases $112.2 million of principal amount of the 3.00% convertible notes due September 1, 2024 (“2024 Notes”), representing approximately 37% of the outstanding 2024 Notes
  • Estimated excess cash proceeds of approximately $14.2 million will be added to the balance sheet
  • Eliminates approximately 2.3 million shares of potential future dilution upon conversion of the notes
  • Creates flexible debt structure with a more balanced mix of secured and unsecured tranches
  • Radius reaffirms 2021 financial guidance
  • Funding provided by MidCap Financial and additional lenders via an amendment and restatement of Radius’ existing loan agreement

BOSTON, March 03, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that the Company has entered into amended and restated credit facilities in the aggregate principal amount of $175 million, consisting of a $150 million term loan, which includes a cashless conversion of $25 million in existing term loans, and a $25 million revolving credit facility. The amended and restated credit facilities also provide for an additional $25 million term loan at the lenders’ discretion. The transaction represents a significant upsize from the Company’s prior senior $95 million loan facilities, which consisted of a $55 million term loan ($25 million of which had been drawn) and a $20 million revolving credit facility that also included an additional $20 million of potential incremental availability. The amended and restated loan is expected to close on or about March 11.

Jim Chopas, the Company’s Principal Finance and Accounting Officer said “this transaction demonstrates the Company’s improved financial strength and ability to access the debt capital markets on what we see as favorable terms to fund its corporate objectives. We expect the increase in cash interest expense to be absorbed by the Company’s cash flow.”

Proceeds from the transaction are expected to be used in the following three ways:

  1. Repurchase $112.2 million of aggregate principal amount of the Company’s existing 3.00% Convertible Senior Notes due September 1, 2024
  2. Rollover the existing $25 million term loan into the new loan
  3. Add $14.2 million of cash to the balance sheet, increasing liquidity as of 12/31/2020 on a pro forma basis from $114.7 million to $128.9 million, subject to change based on adjustments to the aggregate repurchase price of the 2024 Notes over the VWAP Period

The expected aggregate repurchase price of the 2024 Notes is $105.7 million, inclusive of accrued interest, which represents a discount of 6% to face value and convertible debt cancellation of $6.7 million. The aggregate repurchase price is subject to adjustment based in part on the daily volume-weighted average prices per share of the Company’s common stock during a ten-trading day pricing period (“VWAP Period”) following execution of the Repurchase Agreements. As a result of the transaction, the Company’s annual cash interest expense will increase by approximately $6.3 million, driven by the higher term loan interest rate relative to the 2024 Notes.

The 2024 Notes repurchase is expected to close on March 18, 2021, subject to customary closing conditions. 

J. Wood Capital Advisors LLC was the exclusive advisor to Radius in the financing transaction and in the repurchase of the 2024 Notes.

TRANSACTION OVERVIEW AND RATIONALE

Balance Sheet

  • Eliminates approximately 2.3 million shares of potential future dilution upon conversion of the notes
  • Reduces the risk of a convertible note reissuance at a lower strike price to extend the maturity
  • Provides an additional $14.2 million of liquidity to the balance sheet, subject to change based on adjustments to the aggregate repurchase price of the 2024 Notes over the VWAP Period
  • Demonstrates access to the secured debt market at scale and at a manageable cost
  • Creates a tranche of prepayable debt that allows the company to reduce debt ahead of stated maturities in 2024
  • Pro forma, Radius will have $150 million of prepayable debt and $192.8 million of non-prepayable debt
  • Initial step in optimizing the Company’s capital structure and balance sheet in the intermediate term

Income Statement and Cash Flow

  • Incremental cash interest expense from the transaction is approximately $6.3 million on an annual basis and is expected to be manageable given the Company’s anticipated improvement in cash flow
  • Radius reaffirms 2021 financial guidance of generating $10 million of positive EBITDA
  • The Company views the increased interest expense as modest relative to the benefits of the transaction

Peter Schwartzman, the Company’s Capital and Strategy Officer, added “the financing demonstrates the Company’s dedication to strategic management of its capital structure. This transaction reduces future potential equity dilution, adds incremental liquidity, and represents an initial phase of a long-term balance sheet strategy to enhance both operating and financing flexibility.” Mr. Schwartzman continued, “the completion of the transaction is a significant advancement of the Company’s financial position, which will enable Radius to achieve both short and intermediate term objectives. We would like to thank MidCap and its partners for their participation and for enabling this transaction.”

Pro Forma Capitalization Table

  Actual   Pro Forma


 
$ in thousands 12/31/2020 Adjustment


12/31/2020


 
Cash, cash equivalents and marketable securities $114,716 $14,1731 $128,8891  
         
Revolving credit facility  
Term loan2 $25,000 $125,000 $150,000  
Convertible notes payable2 $305,000 ($112,247) $192,753  
Total Debt $
330,000
$
12,753
$
342,753
 

Source: 2020 10-K and financing documents
1 Subject to change based on adjustments to the aggregate repurchase price of the 2024 Notes over the VWAP Period
2 Face value, refer to notes in 10-K

ABOUT THE TRANSACTION

The Company and certain of its subsidiaries (the “Borrowers”) amended and restated its existing senior secured facilities (“Facilities”) with MidCap Financial and MidCap Funding IV Trust, as agents under the term loan credit agreement and revolving loan credit agreement, respectively, and the lenders thereunder.

The term loan credit agreement provides for, among other things:

  • An initial term loan of $150 million, including the cashless conversion of $25 million in existing term loans (the “Initial Term Loan”)
  • An additional $25 million term loan, which the lenders may make available in their discretion within one year of the closing of the Initial Term Loan
  • Interest at a rate of LIBOR plus 5.75%, subject to a 2.00% LIBOR floor

The amended and restated revolving loan agreement provides for, among other things:

  • A revolving credit facility of up to $25 million, made available based on a borrowing base calculated based on percentages of
    • the net collectable value of certain of the Borrowers’ domestic accounts receivable, and
    • domestic eligible inventory,
    • minus certain reserves
  • Interest at a rate of LIBOR plus 3.50%, subject to a 2.00% LIBOR floor

The Facilities have a maturity date of June 1, 2024. They are guaranteed and secured by substantially all of the assets of the Borrowers and any future subsidiaries of the Borrowers that become borrowers or guarantors under the Facilities, subject to certain exceptions. The Borrowers may be required to make mandatory prepayments prior to maturity under certain circumstances.

The foregoing description of the amended and restated credit agreements and facilities is qualified in its entirety by reference to the full text of the Credit Agreements, which will be filed as exhibits to our corresponding Current Report on Form 8-K, to be filed within four business days of the date hereof.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

About MidCap Financial

MidCap Financial is a middle market focused specialty finance firm that was formed in 2008. As of December 31, 2020, MidCap Financial, and its subsidiaries, provides management or other services for over $29.8 billion of commitments, of which $5 billion is managed by MidCap Financial Services Capital Management, LLC, our registered investment advisor.

MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, Inc. pursuant to an investment management agreement. Apollo Global Management, Inc. is one of the world’s largest asset managers with approximately $455.0 billion of assets under management as of December 31, 2020.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including those related to the purchase price to be paid for the 2024 Notes, the closing date of the repurchase, the use of the term loan proceeds, achievement of our corporate and strategic objectives and our ability to absorb interest expense by cash flow. These forward-looking statements are based on management’s current expectations. These statements involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the results of regulatory submissions and oversight; success of our commercial operations; success of our clinical trials and preclinical studies; risks related to manufacturing, supply, and distribution; success of any collaboration, partnership, license or similar agreements; achievement of milestones; receipt of royalties or other future contingent payments; ability to implement pricing increases; ability of the company to access additional secured debt in the future. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2020 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor & Media Relations Contact:

Peter A. Schwartzman
Email: [email protected]
Phone: (617) 583-2017



Uniti Group Inc. to Present at the Citi 2021 Global Property CEO Conference

LITTLE ROCK, Ark, March 03, 2021 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its President and Chief Executive Officer, Kenny Gunderman, and Executive Vice President, Chief Financial Officer and Treasurer, Mark Wallace, are scheduled to participate at the Citi 2021 Global Property CEO Conference. The presentation is scheduled for 4:15 PM ET on March 10, 2021.

You may access a live webcast of the virtual event on Uniti’s website at www.uniti.com under the Investors tab. The webcast will be available for replay for a limited time on Uniti’s website following the presentation.

ABOUT UNITI

Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of wireless infrastructure solutions for the communications industry. As of December 31, 2020, Uniti owns over 123,000 fiber route miles, approximately 6.9 million fiber strand miles, and other communications real estate throughout the United States. Additional information about Uniti can be found on its website at www.uniti.com.

INVESTOR AND MEDIA CONTACTS:

Mark A. Wallace, 501-850-0866
Executive Vice President, Chief Financial Officer & Treasurer
[email protected]

Bill DiTullio, 501-850-0872
Vice President, Finance and Investor Relations
[email protected]



Baosheng Media Group Holdings Limited Announces Full Exercise of Underwriters’ Over-Allotment Option

Beijing, China, March 03, 2021 (GLOBE NEWSWIRE) — Baosheng Media Group Holdings Limited (the “Company”) (Nasdaq: BAOS), a China-based online marketing solution provider, today announced the underwriters of its initial public offering (“Offering”) have exercised in full their option to purchase an additional 900,000 ordinary shares at a public offering price of $5.00 per share to cover overallotments. Gross proceeds of the Company’s initial public offering, including the exercise of the overallotment, totaled $34.5 million, before deducting underwriting discounts and other related expenses. The ordinary shares began trading on the Nasdaq Capital Market on February 8, 2021 under the ticker symbol “BAOS”.

Proceeds from the Offering will be used for expanding the Company’s business scale and securing authorized agency status of additional media, building its own network of key opinion leaders, expanding its manpower and talent pool, and for general working capital purposes.

The Offering was conducted on a firm commitment basis. Univest Securities, LLC acted as the representative of the underwriters and sole book-running manager for the Offering. Hunter Taubman Fischer & Li LLC acted as counsel to the Company, and Ortoli Rosenstadt LLP acted as counsel to Univest Securities, LLC in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the Securities and Exchange Commission (“SEC”) (File Number: 333-239800) and was declared effective by the SEC on February 5, 2021, and a registration statement filed pursuant to Rule 462(b) (File No. 333- 252826) which increased the number of registered shares from 5,000,000 to 6,000,000 became effective upon filing with the SEC. The Offering was made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering may be obtained from Univest Securities, LLC, by email at [email protected] or standard mail to Univest Securities, LLC, Attn: 375 Park Avenue, 15th Floor, New York, NY 10152. In addition, a copy of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Baosheng Media Group Holdings Limited

Baosheng Media Group Holdings Limited, headquartered in Beijing, China, is an online marketing solution provider in China. The Company advises advertisers on online marketing strategies, offers value-added advertising optimization services and facilitates the deployment of online ads of various forms such as search ads, in-feed ads, mobile app ads and social media marketing ads. The Company is dedicated to helping its advertiser clients manage their online marketing activities with a view to achieving their business goals. For more information, visit the company’s website at http://ir.bsacme.com/.

About Univest Securities, LLC

Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-add service and focuses on building long-term relationship with its clients. For more information, please visit: www.univest.us.


Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Ascent Investors Relations LLC

Tina Xiao

President

Phone: 917-609-0333
Email: [email protected]



The Hillman Group Reports Record Fourth Quarter and Full Year 2020 Results

  • Focused execution and solid demand drove record fourth quarter and full year results
  • Completed a highly successful debt syndication in connection with planned merger with Landcadia III
  • Seeing continued strong business momentum in 2021
  • Earnings conference call to be held on March 4, 2021 at 8:30 AM ET

CINCINNATI and HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) — The Hillman Companies, Inc. (NYSE-AMEX: HLM.PR) (the “Company” or “Hillman”) reported today selected financial results for the fourth quarter and full year ended December 26, 2020.

Fourth Quarter 2020 Highlights

  • Net sales for the fourth quarter of 2020 increased 14.8% to $327.1 million as compared to prior year quarter net sales of $284.8 million
  • Adjusted EBITDA1 increased 22.7% to $43.1 million compared to $35.1 million in the prior year quarter
  • Net loss for the fourth quarter of 2020 was $14.0 million compared to a prior year quarter loss of $30.7 million

Full Year 2020 Highlights

  • Net sales for the full year 2020 increased 12.7% to $1,368.3 million as compared to $1,214.4 million in 2019
  • Adjusted EBITDA1 for the full year 2020 increased 23.8% to $221.2 million compared to $178.7 million in 2019
  • Net loss narrowed to $24.5 million compared to $85.5 million in 2019

Doug Cahill, Chairman and Chief Executive Officer, stated, “The power of the Hillman platform was fully evident in 2020 and I am extremely proud of all that the Hillman team accomplished. Not only did we post record financial results but our sales, service and supply chain teams met record levels of customer demand and delivered Hillman’s unmatched in store service, all while dealing with the substantial disruptions caused by the pandemic.”

Mr. Cahill continued, “We had a strong finish to 2020 and this momentum is continuing into 2021. We are seeing positive tailwinds from repair, remodel, and outdoor living trends as homes transform to meet the needs of work, school, recreation and other activities. We also see continued strong demand for PPE and exciting new initiatives are being launched in our RDS segment. We entered 2021 well situated to drive share gains with our customers, strengthen the moat around our business and deliver another year of solid sales, margins, cash flow and superior returns, and we are off to a strong start.”

1) Adjusted EBITDA is a non-GAAP financial measure. Refer to the “Reconciliation of Adjusted EBITDA” section of this press release for additional information as well as reconciliations between the company’s GAAP and non-GAAP financial results.

Debt Refinancing and Capital Resources
At December 26, 2020, the Company had $21.5 million of cash on our balance sheet and had $1,549.8 million of total debt outstanding. The Company had $154.4 million of availability under its revolving credit facility.

As separately announced today, the Company successfully completed the syndication of $1.185 billion in new term loan commitments in a four times oversubscribed transaction. The term loans will be used in connection with and contingent upon the Company’s planned merger with Landcadia Holdings III Inc. (“Landcadia III”), a publicly-traded special purpose acquisition company, to repay all existing outstanding indebtedness. In addition, the financing includes a $250 million, five-year asset-based revolving credit facility, also contingent on closing of the merger with Landcadia III. Through the merger, refinancing and related transactions, the Company will simplify its capital structure and substantially lower expected total cash interest costs.

Planned Merger with Landcadia III

On January 25, 2021, Hillman and Landcadia III announced that they entered into a definitive merger agreement that will result in Hillman becoming a publicly listed company. Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, the combined company will be named Hillman Solutions Corp. and remain listed on Nasdaq under the new ticker symbol “HLMN.”

Conference Call and Webcast

The Company will host a conference call to discuss the financial results for the fourth quarter and full year ended December 26, 2020 on Thursday, March 4, 2021, at 8:30 am Eastern time.   Participants may join the call by dialing 1-(877)-407-9208 a few minutes before the call start time. A live audio webcast of the conference call will also be available in a listen-only mode on the Investor Info page of the Company’s website, which is located at www.hillmangroup.com. Participants who want to access the webcast should visit the company’s website about five minutes before the call. The archived webcast will be available for replay on the company’s website after the call.

About Hillman

Founded in 1964 and headquartered in Cincinnati, Ohio, Hillman is a leading North American provider of complete hardware solutions, delivered with industry best customer service to over 40,000 locations. Hillman designs innovative product and merchandising solutions for complex categories that deliver an outstanding customer experience to home improvement centers, mass merchants, national and regional hardware stores, pet supply stores, and OEM & Industrial customers. Leveraging a world-class distribution and sales network, Hillman delivers a “small business” experience with “big business” efficiency. For more information on Hillman, visit https://www.hillmangroup.com/us/en.

Landcadia Holdings III, Inc.

Landcadia III is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Landcadia III’s sponsors are TJF, LLC, which is wholly-owned by Mr. Fertitta, and Jefferies Financial Group Inc. Landcadia III’s management team is led by Mr. Fertitta, its Chief Executive Officer and Co-Chairman of its Board of Directors and the sole shareholder, Chairman and Chief Executive Officer of Fertitta Entertainment, Inc., and Mr. Handler, Landcadia III’s President, other Co-Chairman of its Board of Directors and the Chief Executive Officer of Jefferies Financial Group Inc. Landcadia III raised $500,000,000 in its initial public offering in October 2020 and is listed on Nasdaq under the ticker symbol “LCY.”

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s and Landcadia III’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s and Landcadia III’s expectations with respect to future performance and anticipated financial impacts of the proposed business combination, the satisfaction of the closing conditions to the proposed transaction and the timing of the completion of the proposed transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company’s and Landcadia III’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the risk that the proposed business combination disrupts the Company’s current plans and operations; (2) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth profitably and retain its key employees; (3) costs related to the proposed business combination; (4) changes in applicable laws or regulations; (5) the possibility that Landcadia III or the Company may be adversely affected by other economic, business, and/or competitive factors; (6) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (7) the outcome of any legal proceedings that may be instituted against Landcadia III or the Company following the announcement of the merger agreement; (8) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of Landcadia III or Hillman, certain regulatory approvals or satisfy other conditions to closing in the merger agreement; (9) the impact of COVID-19 on the Company’s business and/or the ability of the parties to complete the proposed business combination; (10) the inability to obtain or maintain the listing of the combined company’s shares of common stock on Nasdaq following the proposed transaction; or (11) other risks and uncertainties indicated from time to time in the registration statement containing the proxy statement/prospectus relating to the proposed business combination, including those under “Risk Factors” therein, and in Landcadia III’s or the Company’s other filings with the SEC. The foregoing list of factors is not exclusive, and readers should also refer to those risks that will be included under the header “Risk Factors” in the registration statement on Form S-4 filed by Landcadia III with the SEC and those included under the header “Risk Factors” in the final prospectus of Landcadia III related to its initial public offering. Readers are cautioned not to place undue reliance upon any forward-looking statements in this press release, which speak only as of the date made. Landcadia III and the Company do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this press release to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information and Where to Find It

In connection with the proposed business combination, Landcadia III filed a registration statement on Form S-4 with the Securities and Exchange Commission (the “SEC”), which includes a proxy statement/prospectus, that will be both the proxy statement to be distributed to holders of Landcadia III’s common stock in connection with its solicitation of proxies for the vote by Landcadia III’s stockholders with respect to the proposed business combination and other matters as may be described in the registration statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the business combination. After the registration statement is declared effective, Landcadia III will mail a definitive proxy statement/prospectus and other relevant documents to its stockholders. This document does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. Landcadia III’s stockholders, the Company’s stockholders and other interested persons are advised to read the preliminary proxy statement/prospectus included in the registration statement and, when available, the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about the Company, Landcadia III and the business combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to stockholders of Landcadia III as of a record date to be established for voting on the proposed business combination. Landcadia III’s stockholders and the Company’s stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Landcadia Holdings III, Inc., 1510 West Loop South, Houston, Texas 77027, Attention: General Counsel, (713) 850-1010.

Participants in the Solicitation

Landcadia III and Hillman and their respective directors and officers may be deemed participants in the solicitation of proxies of Landcadia III’s stockholders in connection with the proposed business combination. A list of the names of Landcadia III’s directors and executive officers and a description of their interests in Landcadia III is contained in Landcadia III’s registration statement on Form S-4 containing the proxy statement / prospectus for the business combination, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov. Information about the Company’s directors and executive officers is available in Hillman’s Form 10-K for the year ended December 26, 2020 and certain of its Current Reports on Form 8-K.

Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Landcadia III stockholders in connection with the proposed business combination is set forth in the registration statement on Form S-4 containing the proxy statement / prospectus for the business combination. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed business combination is included in the proxy statement that Landcadia III filed with the SEC, including Jefferies Financial Group Inc.’s and/or its affiliate’s various roles in the transaction. You should keep in mind that the interest of participants in such solicitation of proxies may have financial interests that are different from the interests of the other participants. These documents can be obtained free of charge from the sources indicated above.

Contacts

Investor Relations

Rodny Nacier / Brad Cray [email protected]
(513) 826-5495

Public Relations

Phil Denning / Doug Donsky
[email protected]



THE HILLMAN COMPANIES, INC. AND SUBSIDIARIES

Consolidated Statement of Operating Income, GAAP Basis

(dollars in thousands)

Unaudited

  Thirteen Weeks Ended
December 26,
2020
  Thirteen Weeks Ended
December 28,
2019

As Restated

(1)
  Year Ended

December 26,
2020
  Year Ended

December 28,
2019

As Restated

(1)
Net sales $ 327,069       $ 284,798       $ 1,368,295       $ 1,214,362    
Cost of sales (exclusive of depreciation and amortization shown separately below) 191,521       170,065       781,815       693,881    
Selling, general and administrative expenses 106,416       94,084       398,472       382,131    
Depreciation 16,750       16,918       67,423       65,658    
Amortization 14,896       14,796       59,492       58,910    
Management fees to related party 126       166       577       562    
Other (income) expense (3,130 )     (162 )     (5,250 )     5,525    
Income from operations 490       (11,069 )     65,766       7,695    
Interest expense, net 19,028       24,104       86,774       101,613    
Interest expense on junior subordinated debentures 3,152       3,152       12,707       12,608    
Investment income on trust common securities (1,547 )     (3,595 )     (378 )     (378 )  
Loss on mark-to-market adjustment of interest rate swap 884       2,892       601       2,608    
Loss before income taxes (21,027 )     (37,622 )     (33,938 )     (108,756 )  
Income tax benefit (7,065 )     (6,896 )     (9,439 )     (23,277 )  
Net loss $ (13,962 )     $ (30,726 )     $ (24,499 )     $ (85,479 )  

(1) We have restated our financial statements for 2019 due to the correction of errors in the technical accounting for income taxes related to the valuation allowance against deferred tax assets, which impacted our net deferred tax liabilities. See our previously filed 8-K for details on the restatement.

THE HILLMAN COMPANIES, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(dollars in thousands)

Unaudited

  December 26, 2020   December 28, 2019
      As Restated

(1)
ASSETS      
Current assets:      
Cash and cash equivalents $ 21,520       $ 19,973    
Accounts receivable, net of allowances of $2,395 ($1,891 – 2019) 121,228       88,374    
Inventories, net 391,679       323,496    
Other current assets 19,280       8,828    
Total current assets 553,707       440,671    
Property and equipment, net of accumulated depreciation of $236,031 ($179,791 – 2019) 182,674       205,160    
Goodwill 816,200       815,850    
Other intangibles, net of accumulated amortization of $291,434 ($232,060 – 2019) 825,966       882,430    
Operating lease right of use assets 76,820       81,613    
Deferred tax asset 2,075       702    
Other assets 11,176       11,557    
Total assets $ 2,468,618       $ 2,437,983    
LIABILITIES AND STOCKHOLDER’S EQUITY      
Current liabilities:      
Accounts payable $ 201,461       $ 125,042    
Current portion of debt and capital lease obligations 11,481       11,358    
Current portion of operating lease liabilities 12,168       11,459    
Accrued expenses:      
Salaries and wages 29,800       12,937    
Pricing allowances 6,422       6,553    
Income and other taxes 5,986       5,248    
Interest 12,988       14,726    
Other accrued expenses 31,605       21,545    
Total current liabilities 311,911       208,868    
Long-term debt 1,535,508       1,584,289    
Deferred tax liabilities 156,118       164,343    
Operating lease liabilities 68,934       73,227    
Other non-current liabilities 31,560       33,287    
Total liabilities 2,104,031       2,064,014    
       
Commitments and Contingencies (Note 15)          
Stockholder’s Equity:      
Preferred stock, $0.01 par, 5,000 shares authorized, none issued and outstanding at December 26, 2020 and December 28, 2019          
Common stock, $0.01 par, 5,000 shares authorized, issued and outstanding at December 26, 2020 and December 28, 2019          
Additional paid-in capital 565,824       553,359    
Accumulated deficit (171,849 )     (147,350 )  
Accumulated other comprehensive loss (29,388 )     (32,040 )  
Total stockholder’s equity 364,587       373,969    
Total liabilities and stockholder’s equity $ 2,468,618       $ 2,437,983    

 

(1) We have restated our financial statements for 2019 due to the correction of errors in the technical accounting for income taxes related to the valuation allowance against deferred tax assets, which impacted our net deferred tax liabilities. See our previously filed 8-K for details on the restatement.


THE HILLMAN COMPANIES, INC. AND SUBSIDIARIES

Consolidated Statement of Cash Flows

(dollars in thousands)

Unaudited

  Year Ended

December 26,
2020
  Year Ended

December 28,
2019

As Restated

(1)
Cash flows from operating activities:      
Net loss $ (24,499 )     $ (85,479 )  
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 126,915       124,568    
Loss (gain) on dispositions of property and equipment 161       (573 )  
Impairment of long lived assets 210       7,887    
Deferred income taxes (9,462 )     (23,586 )  
Deferred financing and original issue discount amortization 3,722       3,726    
Loss on debt restructuring          
Stock-based compensation expense 5,125       2,981    
Change in fair value of contingent consideration (3,515 )        
Other non-cash interest and change in value of interest rate swap 601       2,608    
Changes in operating items:      
Accounts receivable (32,417 )     22,863    
Inventories (67,147 )     (3,205 )  
Other assets (10,743 )     2,878    
Accounts payable 76,031       (11,975 )  
Other accrued liabilities 27,098       9,666    
Net cash provided by operating activities 92,080       52,359    
Cash flows from investing activities:      
Acquisitions of businesses, net of cash acquired (800 )     (6,135 )  
Capital expenditures (45,274 )     (57,753 )  
Proceeds from sale of property and equipment       10,400    
Net cash used for investing activities (46,074 )     (53,488 )  
Cash flows from financing activities:      
Repayments of senior term loans (10,608 )     (10,608 )  
Borrowings of revolving credit loans 99,000       43,500    
Repayments of revolving credit loans (140,000 )     (38,700 )  
Financing fees       (1,412 )  
Principal payments under capitalized lease obligations (836 )     (683 )  
Proceeds from exercise of stock options 7,340       100    
Proceeds from sale of Holdco stock       750    
Net cash (used for) provided by financing activities (45,104 )     (7,053 )  
Effect of exchange rate changes on cash 645       (79 )  
Net increase (decrease) in cash and cash equivalents 1,547       (8,261 )  
Cash and cash equivalents at beginning of period 19,973       28,234    
Cash and cash equivalents at end of period $ 21,520       $ 19,973    

(1) We have restated our financial statements for 2019 due to the correction of errors in the technical accounting for income taxes related to the valuation allowance against deferred tax assets, which impacted our net deferred tax liabilities. See our previously filed 8-K for details on the restatement.

   

THE HILLMAN COMPANIES, INC. AND SUBSIDIARIES

RECONCILIATION OF ADJUSTED EBITDA (Unaudited)

(dollars in thousands)

Adjusted EBITDA is a non-GAAP financial measure and is the primary basis used to measure the operational strength and performance of our businesses as well as to assist in the evaluation of underlying trends in our businesses. This measure eliminates the significant level of noncash depreciation and amortization expense that results from the capital-intensive nature of our businesses and from intangible assets recognized in business combinations. It is also unaffected by our capital and tax structures, as our management excludes these results when evaluating our operating performance. Our management and Board of Directors use this financial measure to evaluate our consolidated operating performance and the operating performance of our operating segments and to allocate resources and capital to our operating segments. Additionally, we believe that Adjusted EBITDA is useful to investors because it is one of the bases for comparing our operating performance with that of other companies in our industries, although our measure of Adjusted EBITDA may not be directly comparable to similar measures used by other companies.

We have restated our financial statements for 2019 due to the correction of errors in the accounting for income taxes related to the valuation allowance against deferred tax assets, which impacted our net deferred tax liabilities. Accordingly, the EBITDA reconciliation below has been restated. There was no impact to EBITDA or Adjusted EBITDA in 2019. The following table presents a reconciliation of Net loss, the most directly comparable financial measures under GAAP, to Adjusted EBITDA for the periods presented:

  Thirteen Weeks Ended
December 26,
2020
  Thirteen Weeks Ended
December 28,
2019

As Restated
  Year Ended

December 26,
2020
  Year Ended

December 28,
2019

As Restated
Net loss $ (13,962 )     $ (30,726 )     $ (24,499 )     $ (85,479 )  
Income tax (benefit) expense (7,065 )     (6,896 )     (9,439 )     (23,277 )  
Interest expense, net 19,028       24,104       86,774       101,613    
Interest expense on junior subordinated debentures 3,152       3,152       12,707       12,608    
Investment income on trust common securities (1,547 )     (3,595 )     (378 )     (378 )  
Depreciation 16,750       16,918       67,423       65,658    
Amortization 14,896       14,796       59,492       58,910    
Mark-to-market adjustment on interest rate swaps 884       2,892       601       2,608    
EBITDA $ 32,136       $ 20,645       $ 192,681       $ 132,263    
               
Stock compensation expense 1,307       1,075       5,125       2,981    
Management fees 126       166       577       562    
Facility exits (1) 428             3,894          
Restructuring (2) 1,475       9,183       4,902       13,749    
Litigation expense (3) 2,066       651       7,719       1,463    
Acquisition and integration expense (4) 7,788       1,319       9,832       12,557    
Change in fair value of contingent consideration (2,215 )           (3,515 )        
Buy-back expense (5)       1,113             7,196    
Asset impairment charges (6)       991             7,887    
Adjusted EBITDA $ 43,111       $ 35,143       $ 221,215       $ 178,658    

(1) Facility exits include costs associated with the closure of facilities in Parma, Ohio, San Antonio, Texas, and Dallas, Texas.
(2) Restructuring includes restructuring costs associated with restructuring in our Canada segment announced in 2018, including facility consolidation, stock keeping unit rationalization, severance, sale of property and equipment, and charges relating to exiting certain lines of business. Also included is restructuring in our United Stated business announced in 2019, including severance related to management realignment and the integration of sales and operating functions. Finally, includes consulting and other costs associated with streamlining our manufacturing and distribution operations.
(3) Litigation expense includes legal fees associated with our ongoing litigation with KeyMe, Inc.
(4) Acquisition and integration expense includes professional fees, non-recurring bonuses, and other costs related to historical acquisitions.
(5) Buy-back expense includes one-time payments made to customers associated with the new product line roll outs for construction fastener products and builders hardware.
(6) Asset impairment charges includes impairment losses for the disposal of FastKey self-service key duplicating kiosks and related assets



VOYAGER THERAPEUTICS, INC.  CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Voyager Therapeutics, Inc.

LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ: VYGR) in the United States District Court for the Eastern District of New York on behalf of a class consisting of all investors that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, inclusive (the “Class Period”).

All investors who purchased shares of
Voyager Therapeutics, Inc.
and incurred losses are urged to contact the firm immediately at

[email protected]

or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or

join the case

on our website,

www.whafh.com

.

If you have incurred losses in the shares of Voyager Therapeutics, Inc., you may,no later than March 24, 2021, request that the Court appoint you lead plaintiff of the proposed class.  Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Voyager Therapeutics, Inc. 

CLICK HERE TO JOIN CASE

Voyager, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases.  Included in the Company’s preclinical programs is VY-HTT01 for Huntington’s Disease. 

On June 1, 2017, Voyager issued a press release announcing that it had selected VY-HTT01 as a lead clinical candidate for the treatment of Huntington’s disease.  The press release also indicated that, [p]reclinical pharmacology and toxicology studies [were] underway with VY-HTT01 to support filing of an investigational new drug (IND) application in 2018.”

In September 2020, Voyager submitted an investigational new drug (“IND”) application for VY-HTT01 for the treatment of Huntington’s disease to the U.S. Food and Drug Administration (“FDA”).

On October 12, 2020, Voyager issued a press release disclosing that it “has received feedback from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for VY-HTT01 for the treatment of Huntington’s disease.”  Specifically, Voyager advised investors that it “has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.”

Then, on November 9, 2020, Voyager issued a press release announcing the Company’s third quarter 2020 financial results and corporate updates.  In the press release, the Company disclosed that, with respect to its IND application for VY-HTT01, “Voyager recently received written feedback from the FDA requesting additional information on specific CMC topics, including drug-device compatibility and drug substance and product characterization.”

On this news, Voyager’s stock price fell $2.60 per share, or 23.21%, to close at $8.60 per share on November 10, 2020.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



nLIGHT, Inc. Announces Proposed Public Offering of Common Stock

nLIGHT, Inc. Announces Proposed Public Offering of Common Stock

VANCOUVER, Wash.–(BUSINESS WIRE)–
nLIGHT, Inc. (Nasdaq:LASR) today announced that it has commenced a proposed underwritten public offering of its common stock pursuant to its existing shelf registration statement. In connection with the proposed offering, nLIGHT expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering, at the public offering price, less the underwriting discounts and commissions. nLIGHT intends to use the net proceeds from the proposed offering for working capital, capital expenditures and other general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Stifel and Raymond James are acting as lead book-running managers for the proposed offering.

An automatically effective registration statement, including a base prospectus, relating to the securities was filed with the Securities and Exchange Commission (“SEC”) on March 3, 2021. The offering will be made only by means of a prospectus supplement and the accompanying prospectus that forms part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at 415-364-2720 or by email at [email protected]; or Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, FL 33716, by telephone at 800-248-8863 or by email at [email protected]. Before investing in our common stock, investors should read the preliminary prospectus supplement and the accompanying prospectus, including the documents incorporated by reference therein, and any free writing prospectus related to this offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Safe Harbor Statement

Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the proposed public offering, including statements regarding the timing and completion of the proposed public offering, nLIGHT’s intended use of the net proceeds from the offering and other references to future periods. Forward-looking statements are based on our current expectations and assumptions, which may not prove to be accurate. These statements are not guarantees and are subject to risks, uncertainties and changes in circumstances that are difficult to predict. Many factors could cause actual results to differ materially and adversely from these forward-looking statements, including but not limited to the factors and uncertainties identified in the “Risk Factors” section of nLIGHT’s most recent Annual Report on Form 10-K or subsequent filings with the SEC. nLIGHT undertakes no obligation to update publicly or revise any forward-looking statements contained herein to reflect future events or developments, except as required by law.

Investor Relations Contact:

Joseph Corso

VP, Corporate Development and Investor Relations

nLIGHT, Inc.

(360) 566-4460

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Defense Other Defense Other Manufacturing Technology Aerospace Semiconductor Manufacturing Other Technology

MEDIA:

Aflac Incorporated President and Chief Operating Officer Frederick J. Crawford to Participate in Panel Discussion at 2021 RBC Capital Markets Global Financials Conference

PR Newswire

COLUMBUS, Ga., March 3, 2021 /PRNewswire/ — Aflac Incorporated (NYSE: AFL) announced today that Aflac Incorporated President and Chief Operating Officer Frederick J. Crawford will participate in a panel discussion at the 2021 RBC Capital Markets Global Financials Conference on Wednesday, March 10, 2021 at 8:00 a.m. ET. The panel discussion will cover the role of the financial sector in building a more sustainable future.

The panel will be webcast live at:

https://event.on24.com/wcc/r/3034576/83370C59CD813D982883AACD1964A82C

Those who want to listen should go to the website at least 15 minutes prior to the presentation to download and install any necessary software. A replay of the presentation will be available for one year at the same website beginning one hour after the presentation concludes.

ABOUT AFLAC INCORPORATED
Aflac Incorporated (NYSE: AFL) is a Fortune 500 company, helping provide protection to more than 50 million people through its subsidiaries in Japan and the U.S., where it is a leading supplemental insurer by paying cash fast when policyholders get sick or injured. For more than six decades, insurance policies of Aflac Incorporated’s subsidiaries have given policyholders the opportunity to focus on recovery, not financial stress. Aflac Life Insurance Japan is the leading provider of medical and cancer insurance in Japan, where it insures 1 in 4 households. Fortune magazine recognized Aflac as one of the 100 Best Companies to Work for in America for 20 consecutive years. For 15 consecutive years, Aflac has been included on Ethisphere’s list of the World’s Most Ethical Companies. In 2021, Fortune included Aflac Incorporated on its list of World’s Most Admired Companies for the 20th time, and Bloomberg added Aflac Incorporated to its Gender-Equality Index for the second time, which tracks the financial performance of public companies committed to supporting gender equality through policy development, representation and transparency. To learn how to get help with expenses health insurance doesn’t cover, get to know us at aflac.com.

FORWARD-LOOKING INFORMATION

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. The company desires to take advantage of these provisions. This document contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as “expect,” “anticipate,” “believe,” “goal,” “objective,” “may,” “should,” “estimate,” “intends,” “projects,” “will,” “assumes,” “potential,” “target,” “outlook” or similar words as well as specific projections of future results, generally qualify as forward-looking. Aflac undertakes no obligation to update such forward-looking statements.

The company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements:

  • difficult conditions in global capital markets and the economy, including those caused by COVID-19
  • defaults and credit downgrades of investments
  • exposure to significant interest rate risk
  • concentration of business in Japan
  • limited availability of acceptable yen-denominated investments
  • foreign currency fluctuations in the yen/dollar exchange rate
  • differing judgments applied to investment valuations
  • significant valuation judgments in determination of expected credit losses recorded on the Company’s investments
  • decreases in the Company’s financial strength or debt ratings
  • decline in creditworthiness of other financial institutions
  • the effects of COVID-19, and any resulting economic effects and government interventions, on the Company’s business and financial results
  • ability to attract and retain qualified sales associates, brokers, employees, and distribution partners
  • deviations in actual experience from pricing and reserving assumptions
  • ability to continue to develop and implement improvements in information technology systems
  • interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality or privacy of sensitive data residing on such systems
  • subsidiaries’ ability to pay dividends to the Parent Company
  • inherent limitations to risk management policies and procedures
  • concentration of the Company’s investments in any particular single-issuer or sector
  • events related to the Japan Post investigation and other matters
  • tax rates applicable to the Company may change
  • failure to comply with restrictions on policyholder privacy and information security
  • extensive regulation and changes in law or regulation by governmental authorities
  • competitive environment and ability to anticipate and respond to market trends
  • catastrophic events including, but not necessarily limited to, epidemics, pandemics (such as the coronavirus COVID-19), tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, terrorism or other acts of violence, and damage incidental to such events
  • ability to protect the Aflac brand and the Company’s reputation
  • ability to effectively manage key executive succession
  • changes in accounting standards
  • level and outcome of litigation
  • allegations or determinations of worker misclassification in the United States

 

Analyst and investor contact – David A. Young, 706.596.3264 or 800.235.2667 or [email protected]

Media contact – Ines Gutzmer, 762.207.7601 or [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aflac-incorporated-president-and-chief-operating-officer-frederick-j-crawford-to-participate-in-panel-discussion-at-2021-rbc-capital-markets-global-financials-conference-301239893.html

SOURCE Aflac Incorporated

IAC to Attend 2021 Truist Securities Technology, Internet & Services Conference

PR Newswire

NEW YORK, March 3, 2021 /PRNewswire/ — IAC (NASDAQ: IAC), will attend the 2021 Truist Securities Technology, Internet & Services Conference on Wednesday, March 10, 2021. Glenn Schiffman, Chief Financial Officer of IAC, will participate in a fireside chat at 8:00 a.m. ET.  A live webcast will be available to the public at https://ir.iac.com/.

About IAC
IAC (NASDAQ: IAC) builds companies.  We are guided by curiosity, a questioning of the status quo, and a desire to invent or acquire new products and brands.  From the single seed that started as IAC over two decades ago have emerged 10 public companies and generations of exceptional leaders.  We will always evolve, but our basic principles of financially-disciplined opportunism will never change.  IAC today operates Vimeo, Dotdash and Care.com, among many others, and has majority ownership of ANGI Homeservices, which includes HomeAdvisor, Angie’s List and Handy.  The Company is headquartered in New York City and has business operations and satellite offices worldwide.

Cision View original content:http://www.prnewswire.com/news-releases/iac-to-attend-2021-truist-securities-technology-internet–services-conference-301240007.html

SOURCE IAC

QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics

QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics

  • Major step towards bringing customer service to critical and syndromic testing
  • QIAsphere mobile App enables real-time and remote test monitoring from anywhere, and will be available for additional QIAGEN instruments in coming months
  • QIAstat-Dx customers can benefit from 24/7 remote service to enhance testing continuity

HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.

QIAsphere sets new standards for syndromic testing digital health, providing users with remote visibility of their testing routine. It can monitor a nearly unlimited number of instruments, providing visibility of testing routine across different hospitals or satellite labs. The continuous connectivity to QIAGEN service reduces systems downtime and enabling fast and accurate syndromic testing. Digital diagnostics and remote analytics will be crucial to bring syndromic testing closer to patients in the coming years.

Customers using QIAsphere will be able to remotely monitor their QIAstat-Dx instrument and test status, received push notifications across their personal devices, such as smartphones, desktop PCs and smartwatches.

QIAstat-Dx connectivitywith QIAsphere will also allow QIAGEN technical service to monitor customers instruments health in real-time, whilst providing them with rapid response to minimized systems downtime.

QIAGEN began marketing and distributing QIAsphere for the QIAcube Connect platform in early 2021 and will expand its scope into Molecular Diagnostics with its syndromic testing platform QIAstat-Dx. QIAGEN plans to extend the scope of QIAsphere across many platforms and solutions in the coming months.

“The launch of QIAsphere platform for QIAstat-Dx is a key step in syndromic testing, but above all for our customers: it is our commitment to make their life easier, their testing workflow more manageable and our interactions faster,” said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. “Digital diagnostics sets a new paradigm in syndromic testing. It addresses the growing need of bringing molecular PCR COVID testing closer to patients and to decentralized environments such as ICUs, emergency rooms or satellite labs.”

QIAsphere connectivity is possible by connecting the QIAsphere Base (Qbase), a small connectivity hub, to QIAstat-Dx and other QIAGEN platforms in minimal time through hospitals LAN or Wifi network, keeping sensitive patients data within the hospital network. The Qbase connectivity hub along with QIAsphere App will enable real-time monitoring across all customers QIAstat-Dx analyzers.

For more information on QIAsphere please visit https://www.qiagen.com/clp/qiasphere.

Further information on QIAGEN’s response to the coronavirus outbreak can be found here.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Category: Corporate

QIAGEN

Investor Relations

John Gilardi, +49 2103 29 11711

Phoebe Loh, +49 2103 29 11457

[email protected]

Public Relations

Thomas Theuringer, +49 2103 29 11826

Robert Reitze, +49 2103 29 11676

[email protected]

KEYWORDS: Maryland Switzerland United States Austria North America Europe Germany

INDUSTRY KEYWORDS: Research Mobile/Wireless Technology Hospitals Software Practice Management Biotechnology Pharmaceutical Health Science

MEDIA: